Gracell Biotechnologies Inc expected to post a loss of 13 cents a share - Earnings Preview

Gracell Biotechnologies

10/03/2023 13:36

* Gracell Biotechnologies Inc  GRCL.OQ   GRCL.O  is expected
to show no change in quarterly revenue when it reports 
results on March 13. 
    * 
    * ​Refinitiv's mean analyst estimate for Gracell
Biotechnologies
Inc is for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $12​, above​ its last closing price
of $1.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.18       -0.13      -0.07     Beat    47.2
 Jun. 30 2022  -0.07       -0.07      -0.30     Missed  -300
 Mar. 31 2022  -0.23       -0.21      -0.35     Missed  -66.7​
 Dec. 31 2021  -0.33       -0.33      -0.30     Beat    9.1
 ​​Sep.        -0.15       -0.12      -0.30     Missed  -150
 30 2021                                                
 Jun. 30 2021  -0.12       -0.12      -0.20     Missed  -71.4​
 Mar. 31 2021  -0.21       -0.21      -0.25     Missed  -17.2
 Dec. 31 2020  -0.26       -0.26      -0.16     Beat    37.5
 This summary was machine generated March 10 at 13:36 GMT.  All
figures in US dollars  unless otherwise stated